依达拉奉与尼莫地平联合微创颅内血肿清除术治疗高血压脑出血的效果分析  

Effect analysis of edaravone and nimodipine with minimally invasive intracranial hematoma removal for the treatment of hypertensive cerebral hemorrhage

作　　者：方奕儒 王煜喆 黄焱 FANG Yi-ru;WANG Yu-zhe;HUANG Yan(Zhangzhou Hospital,Zhangzhou 363000,China)

机构地区：[1]漳州市医院,363000

出　　处：《中国现代药物应用》2024年第19期79-82,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究高血压脑出血患者在微创颅内血肿清除术治疗期间联合依达拉奉、尼莫地平治疗的临床效果。方法100例高血压脑出血患者,按照随机的分组原则分为观察组和对照组,各50例。对照组实施微创颅内血肿清除术,观察组在对照组基础上联合依达拉奉注射液与尼莫地平注射液进行治疗。比较两组患者治疗前后的血清炎性因子、凝血功能指标、血肿体积以及预后情况。结果治疗后,两组患者超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均低于治疗前,且观察组患者hs-CRP(13.93±3.25)mg/L、IL-6(34.96±1.48)pg/ml、TNF-α(9.63±0.86)pg/ml均低于对照组的(19.78±4.17)mg/L、(47.64±1.59)pg/ml、(13.52±3.19)pg/ml,具有显著差异(P<0.05)。治疗后,两组患者D二聚体(D-D)均低于治疗前,凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)均短于治疗前,且观察组的D-D(0.82±0.21)mg/L明显低于对照组的(1.39±0.39)mg/L,PT(12.93±0.98)s、APPT(29.63±6.16)s均短于对照组的(14.25±0.96)、(32.52±5.24)s,具有显著差异(P<0.05)。治疗后,观察组血肿体积(3.64±0.31)ml小于对照组的(3.86±0.20)ml,具有显著差异(P<0.05)。观察组预后优良率90.0%高于对照组的52.0%,具有显著差异(P<0.05)。结论高血压脑出血患者实施微创颅内血肿清除术治疗期间联合应用依达拉奉、尼莫地平,可改善患者病症,缩小血肿体积,值得临床借鉴。Objective To explore the clinical effect of edaravone and nimodipine with minimally invasive intracranial hematoma removal for the treatment of hypertensive cerebral hemorrhage.Methods 100 patients with hypertensive cerebral hemorrhage were randomly divided into an observation group and a control group,with 50 patients in single group.The control group underwent minimally invasive intracranial hematoma removal,and the observation group was treated with edaravone injection and nimodipine injection based on the control group.The serum inflammatory factors,blood coagulation indexes,hematoma volume before and after treatment,and prognosis were compared between the two groups.Results After treatment,the levels of hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in both groups were lower than those before treatment;the observation group had hs-CRP of(13.93±3.25)mg/L,IL-6 of(34.96±1.48)pg/ml,and TNF-αof(9.63±0.86)pg/ml,which were lower than(19.78±4.17)mg/L,(47.64±1.59)pg/ml,and(13.52±3.19)pg/ml in the control group;there were significant differences(P<0.05).After treatment,the D-dimer(D-D),prothrombin time(PT)and activated partial thromboplastin time(APTT)in both groups were lower than those before treatment;D-D of(0.82±0.21)mg/L in the observation group was significantly lower than(1.39±0.39)mg/L in the control group;the observation group had PT of(12.93±0.98)s and APPT of(29.63±6.16)s,which shorter than(14.25±0.96)and(32.52±5.24)s in the control group;there were significant differences(P<0.05).After treatment,the hematoma volume of(3.64±0.31)ml in the observation group was smaller than(3.86±0.20)ml in the control group(P<0.05).The rate of excellent prognosis of 90.0%in the observation group was higher than 52.0%in the control group,and there were significant differences(P<0.05).Conclusion The combined application of edaravone and nimodipine during minimally invasive intracranial hematoma removal in patients with hypertensive cerebral hemorrhage can improve

关 键 词：依达拉奉 尼莫地平 微创颅内血肿清除术 高血压脑出血 

分 类 号：R651.12[医药卫生—外科学]